Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 05/14/24 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
   |
23 |
| 05/09/24 | UPLOAD | SEC-generated letter |
|
1 | |
| 05/03/24 | S-1 | General form of registration statement for all companies including face-amount certificate companies |
|
23 | |
| 05/03/24 | 8-K | Current report filing |
|
|
39 |
| 03/11/24 | 8-K | Current report filing |
|
|
4 |
| 03/06/24 | 8-K | Current report filing |
|
|
2 |
| 02/14/24 | 8-K | Current report filing |
|
|
5 |
| 02/14/24 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
21 |
| 02/01/24 | 8-K | Current report filing |
|
|
2 |
| 01/29/24 | 8-K | Current report filing |
|
|
2 |
